U.S. Supreme Court unanimously rules a cardiovascular drugmaker didn’t violate patent laws
In a unanimous decision, the U.S. Supreme Court found that a cardiovascular drugmaker did not violate U.S. patent laws, a ruling that could make it easier for generic manufacturers to produce more drugs without fear of patent claims.
The U.S. Supreme Court issued a unanimous decision finding that a cardiovascular drugmaker did not violate America’s patent laws. The ruling could allow generic drug manufacturers to produce more medicines without fear of patent-related liability.